Abstract
Pharmacokinetic/pharmacodynamic (PK/PD)-modeling links dose-concentration relationships (PK) and concentration-effect relationships (PD), thereby facilitating the description and prediction of the time course of drug effects resulting from a certain dosing regimen. PK/PD-modeling approaches can basically be distinguished by four major attributes. The first characterizes the link between measured drug concentration and the response system, direct link versus indirect link. The second considers how the response system relates effect site concentration to the observed outcome, direct versus indirect response. The third regards what clinically or experimentally assessed information is used to establish the link between concentration and effect, hard link versus soft link. And the fourth considers the time dependency of pharmacodynamic model parameters, distinguishing between time-variant versus time-invariant. Application of PK/PD-modeling concepts has been identified as potentially beneficial in all phases of preclinical and clinical drug development. Although today predominantly limited to research, broader application of PK/PD-concepts in clinical therapy will provide a more rational basis for patient-specific dosage individualization and may thus guide applied pharmacotherapy to a higher level of performance.
Similar content being viewed by others
REFERENCES
G. Levy. Kinetics of drug action: an overview. J. Allergy Clin. Immunol. 78:754–761 (1986).
N. H. G. Holford and L. B. Sheiner. Kinetics of pharmacological response. Pharmacol. Ther. 16:143–166 (1982).
G. Levy, M. Gibaldi, and W. J. Jusko. Multicompartment pharmacokinetic models and pharmacologic effects. J. Pharm. Sci. 58:422–424 (1969).
G. Levy. Kinetics of drug action in man. Acta Pharmacol. Toxicol. Copenh. 29Suppl. 3:203–210 (1971).
M. Gibaldi, G. Levy, and H. Weintraub. Drug distribution and pharmacologic effects. Clin. Pharmacol. Ther. 12:734–742 (1971).
J. G. Wagner. Kinetics of pharmacologic response: I. Proposed relationship between response and drug concentration in the intact animal and man. J. Theor. Biol. 20:173–201 (1968).
L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358–371 (1979).
N. H. G. Holford and L. B. Sheiner. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit. Rev. Bioeng. 5:273–322 (1981).
B. Oosterhuis and C. J. van Boxtel. Kinetics of drug effects in man. Ther. Drug Monit. 10:121–132 (1988).
J. D. Unadkat, F. Bartha, and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin. Pharmacol. Ther. 40:86–93 (1986).
E. Fuseau and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin. Pharmacol. Ther. 35:733–741 (1984).
E. Chan, A. McLachlan, R. O'Reilly, and M. Rowland. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin. Pharmacol. Ther. 56:286–294 (1994).
M. Thibonnier, N. H. G. Holford, R. A. Upton, C. D. Blume, and R. L. Williams. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. J. Pharmacokinet. Biopharm. 12:559–573 (1984).
S. Rohatagi, U. Tauber, K. Richter, and H. Derendorf. Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone. J. Clin. Pharmacol. 36:311–314 (1996).
B. Meibohm and H. Derendorf. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modeling. Int. J. Clin. Pharmacol. Ther. 35:401–413 (1997).
H. Derendorf and G. Hochhaus, Handbook of Pharmacokinetic/Pharmacodynamic Correlation, CRC Press, Boca Raton, 1995.
M. O. Karlsson, V. Molnar, J. Bergh, A. Freijs, and R. Larsson. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin. Pharmacol. Ther. 63:11–25 (1998).
D. E. Nix, J. H. Wilton, J. Hyatt, J. Thomas, L. C. Strenkoski-Nix, A. Forrest, and J. J. Schentag. Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers. Antimicrob. Agents Chemother. 41:1108–1114 (1997).
J. W. Mandema and D. R. Stanski. Population pharmacodynamic model for ketorolac analgesia. Clin. Pharmacol. Ther. 60:619–635 (1996).
C. A. Shanks, M. J. Avram, T. C. Krejcie, T. K. Henthorn, and W. B. Gentry. A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. J. Pharmacokinet. Biopharm. 21:309–321 (1993).
J. W. Blue and W. A. Colburn. Efficacy measures: surrogates or clinical outcomes. J. Clin. Pharmacol. 36:767–770 (1996).
J. W. Lee, J. D. Hulse, and W. A. Colburn. Surrogate biochemical markers: precise measurement for strategic drug and biologics development. J. Clin. Pharmacol. 35:464–470 (1995).
B. G. Reigner, P. E. O. Williams, I. H. Patel, J. L. Steimer, C. C. Peck, and P. van Brummelen. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Clin. Pharmacokinet. 33:142–152 (1997).
V. P. Shah, K. K. Midha, S. Dighe, I. J. McGilveray, J. P. Skelly, A. Yacobi, T. Layloff, et al. Analytical method validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 81:309–312 (1992).
W. A. Colburn. Selecting and validating biologic markers for drug development. J. Clin. Pharmacol. 37:355–362 (1997).
G. Levy. Mechanism-based pharmacodynamic modeling. Clin. Pharmacol. Ther. 56:356–358 (1994).
W. A. Colburn. Pharmacokinetic/pharmacodynamic modeling: what it is! J. Pharmacokinet. Biopharm. 15:545–555 (1987).
A. Racine-Poon, L. Botta, T. W. Chang, F. M. Davis, D. Gygax, R. S. Liou, P. Rohane, et al. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin. Pharmacol. Ther. 62:675–690 (1997).
J. O. Auler, E. B. Espada, E. Crivelli, T. B. G. Quintavalle, A. Kurata, N. A. G. Stolf, A. M. Issy, et al. Diclofenac plasma protein binding: PK-PD modeling in cardiac patients submitted to cardiopulmonary bypass. Braz. J. Med. Biol. Res. 30:369–374 (1997).
G. Hochhaus, E. W. Schmidt, K. L. Rominger, and H. Möllmann. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharm. Res. 9:291–297 (1992).
W. G. Kramer, A. J. Kolibash, R. P. Lewis, M. S. Bathala, J. A. Visconti, and R. H. Reuning. Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man. J. Pharmacokinet. Biopharm. 7:47–61 (1979).
G. Segre. Kinetics of interaction between drugs and biological systems. Farmaco. Sci. 23:907–918 (1968).
W. A. Colburn. Simultaneous pharmacokinetic and pharmacodynamic modeling. J. Pharmacokinet. Biopharm. 9:367–388 (1981).
J. Dingemanse, J. Häussler, W. Hering, H. Ihmsen, S. Albrecht, M. Zell, H. Schwilden, and J. Schüttler. Pharmacokinetic-pharmacodynamic modeling of the EEG effects of RO 48-6791, a new short-acting benzodiazepine, in young and elderly subjects. Br. J. Anaesth. 79:567–574 (1997).
D. E. Salazar, D. R. Much, P. S. Nichola, J. R. Seibold, D. Shindler, and P. H. Slugg. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J. Clin. Pharmacol. 37:799–809 (1997).
R. Nagashima, R. A. O'Reilly, and G. Levy. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin. Pharmacol. Ther. 10:22–35 (1969).
N. L. Dayneka, V. Garg, and W. J. Jusko. Comparision of four basic models of indirect pharmacodynamic responses. J. Pharmocokinet. Biopharm. 21:457–478 (1993).
A. Sharma and W. J. Jusko. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br. J. Clin. Pharmacol. 45:229–239 (1998).
D. Verotta and L. B. Sheiner. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data. J Pharmacokinet. Biopharm. 23:1–4 (1995).
L. B. Sheiner and D. Verotta. Further notes on physiologic indirect response models. Clin. Pharmacol. Ther. 58:238–240 (1995).
M. Wakelkamp, G. Alvan, and G. Paintaud. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide. Br. J. Clin. Pharmacol. 45:63–70 (1998).
S. Rohatagi, A. Bye, C. Falcoz, A. E. Mackie, B. Meibohm, H. Möllmann, and H. Derendorf. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J. Clin. Pharmacol. 36:938–941 (1996).
W. J. Jusko and H. C. Ko. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56:406–419 (1994).
Z. X. Xu, Y. N. Sun, D. C. DuBois, R. R. Almon, and W. J. Jusko. Third-generation model for corticosteroid pharmacodynamics: Roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J. Pharmacokinet. Biopharm. 23:163–181 (1995).
A. I. Nichols, F. D. Boudinot, and W. J. Jusko. Second generation model for prednisolone pharmacodynamics in the rat. J. Pharmacokinet. Biopharm. 17:209–227 (1989).
H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth, M. Krieg, S. Tunn, and C. Möllmann. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J. Clin. Pharmacol. 33:115–123 (1993).
R. E. Jonkers, M. C. P. Braat, R. P. Koopmans, and C. J. van Boxtel. Pharmacodynamic modeling of the drug-induced down-regulation of a β2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. Eur. J. Clin. Pharmacol. 49:37–44 (1995).
B. Meibohm, G. Hochhaus, and H. Derendorf. Time dependency of the pharmacologic response to glucocorticoids. Clin. Pharmacol. Ther. 61:155 (1997).
M. J. Chow, J. J. Ambre, T. I. Ruo, A. J. Atkinson, D. J. Bowsher, and M. W. Fischman. Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin. Pharmacol. Ther. 38:318–324 (1985).
J. J. Ambre. Acute tolerance to pressor effects of cocaine in humans. Ther. Drug Monit. 15:537–540 (1993).
H. C. Porchet, N. L. Benowitz, and L. B. Sheiner. Pharmacodynamic model of tolerance: application to nicotine. J. Pharmacol. Exp. Ther. 244:231–236 (1988).
J. A. Bauer and H. L. Fung. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm. Res. 11:816–823 (1994).
M. Wakelkamp, G. Alvan, J. Gabrielsson, and G. Paintaud. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin. Pharmacol. Ther. 60:75–88 (1996).
Y. Hashimoto and L. B. Sheiner. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. J. Pharmacokinet. Biopharm. 19:333–353 (1991).
L. B. Sheiner and T. M. Ludden. Population pharmacokinetics/dynamics. Ann. Rev. Pharmacol. Toxicol. 32:185–209 (1992).
L. Yuh, S. Beal, M. Davidian, F. Harrison, A. Hester, K. Kowalski, E. Vonesh, and R. Wolfinger. Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. Biometrics 50:566–575 (1994).
S. Vozeh, J. L. Steimer, M. Rowland, P. Morselli, F. Mentre, L. P. Balant, and L. Aarons. The use of population pharmacokinetis in drug development. Clin. Pharmacokinet. 30:81–93 (1996).
C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J. Clin. Pharmacol. 34:111–119 (1994).
P. D. Kroboth, V. D. Schmith, and R. B. Smith. Pharmacodynamic modeling: Application to new drug development. Clin. Pharmacokinet. 20:91–98 (1991).
R. Lieberman and J. McMichael. Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development. Ther. Drug Monit. 18:423–427 (1996).
D. D. Breimer and M. Danhof. Relevance of the application of pharmacokinetic-pharmacodynamic modeling concepts in drug development. Clin. Pharmacokinet. 32:259–267 (1997).
F. Mentre, F. Pousset, E. Comets, B. Plaud, B. Diquet, G. Montalescot, A. Ankri, et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin. Pharmacol. Ther. 63:64–78 (1998).
M. Hale, W. Gillespie, S. Gupta, B. Tuk, and N. H. G. Holford. Clinical trial simulation: Streamlining your drug development process. Appl. Clin. Trials 5:35–40 (1996).
R. Gieschke, B. G. Reigner, and J. L. Steimer. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modeling. Int. J. Clin. Pharmacol. Ther. 35:469–474 (1997).
N. H. G. Holford. The target concentration approach to clinical drug development. Clin. Pharmacokinet. 29:287–291 (1995).
Z. X. Xu, A. Rakhit, I. H. Patel, and P. van Brummelen. PK/PD modeling approach to support clinical development of a long-acting interferon (RO 25-3036) for the treatment of chronic hepatitis C. Clin. Pharmacol. Ther. 63:162 (1998).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Derendorf, H., Meibohm, B. Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives. Pharm Res 16, 176–185 (1999). https://doi.org/10.1023/A:1011907920641
Issue Date:
DOI: https://doi.org/10.1023/A:1011907920641